Moderna Inc. shares fell from an all-time high as investors digested early data from a small trial of the company’s coronavirus vaccine, and a $1.3 billion stock sale announced late Monday.
The shares hit a record Monday, and helped raise the broader market, after the Cambridge, Massachusetts-based company released early data from a study of its experimental vaccine. The study was designed to show that the shot was safe, and it was successful on that front. It also contained data from eight patients showing that it produced markers of an immune response, a hopeful sign that it could be effective in fighting the virus in wider tests.
